You are here

Rheumatoid Arthritis Satisfaction Outcome Research

Last updated on October 15, 2019

FOR MORE INFORMATION
Study Location
Asan Medical Center
Songpa-gu, Seoul, 138-736 Korea, Republic of
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
19 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Patients aged 19 years or older

2. Patients diagnosed with RA

3. Treatment groups:

1) Tofacitinib citrate users: Patients currently on treatment with tofacitinib citrate in
RA therapy for 6 months or more 2) Adalimumab users: Patients currently on treatment with
adalimumab in the RA therapy for 6 months or more 4. Reading and writing with enough
proficiency to complete assessment instruments in Korean

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Patients currently on tofacitinib citrate or adalimumab in RA treatment for 2 year or
more

2. Patients taking concomitant other DMARDs except MTX 

NCT03703817
Cheladv74
Recruiting
Rheumatoid Arthritis Satisfaction Outcome Research

NEED INFO?

Questions about a trial? Call or email to reach a Cheladv74 Clinical Trial Contact Center Representative

Cheladv74 Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Based on your search, you may also be interested in

Rheumatoid Arthritis
NCT03703817
All Genders
19+
Years
Multiple Sites
Systemic Lupus Erythematosus, Rheumatoid Arthritis
NCT03334851
All Genders
18+
Years
Multiple Sites
Descriptive Information
Brief TitleRheumatoid Arthritis Satisfaction Outcome Research
Official TitleTREATMENT SATISFACTION COMPARISON IN RHEUMATOID ARTHRITIS PATIENTS BETWEEN TOFACITINIB CITRATE AND ADALIMUMAB, EACH USED IN RHEUMATOID ARTHRITIS TREATMENT
Brief SummaryRA satisfaction OR: This study aim to compare treatment satisfaction and quality of life between patients who have been using tofacitinib citrate and patients who have been using adalimumab for 6 months or more and less than 2 year in RA treatment of rheumatoid arthritis.
Detailed Description

RA satisfaction OR: This study aim to compare treatment satisfaction and quality of life between patients who have been using tofacitinib citrate and patients who have been using adalimumab for 6 months or more and less than 2 year in RA treatment of rheumatoid arthritis.

Study design: Non-interventional, multi-centers, cross-sectional study

Study TypeObservational
Study DesignObservational Model: Other
Time Perspective: Cross-Sectional
Target Follow-Up DurationNot Provided
BiospecimenNot Provided
Sampling MethodProbability Sample
Study PopulationThe study population is RA patients who have been using tofacitinib citrate or adalimumab for 6 months or more and less than 2 year in RA treatment at participating institution
ConditionRheumatoid Arthritis
InterventionNot Provided
Study Groups/Cohorts
  • tofacitinib citrate users
    patients who have been using tofacitinib citrate for 6 months or more and less than 2 year in RA patients
  • adalimumab users
    patients who have been using adalimumab for 6 months or more and less than 2 year in RA patients
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment StatusRecruiting
Estimated Enrollment
 (submitted: October 10, 2018)
840
Original Estimated EnrollmentSame as current
Estimated Study Completion DateDecember 31, 2019
Estimated Primary Completion DateDecember 31, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  1. Patients aged 19 years or older
  2. Patients diagnosed with RA
  3. Treatment groups:

1) Tofacitinib citrate users: Patients currently on treatment with tofacitinib citrate in RA therapy for 6 months or more 2) Adalimumab users: Patients currently on treatment with adalimumab in the RA therapy for 6 months or more 4. Reading and writing with enough proficiency to complete assessment instruments in Korean

Exclusion Criteria:

  1. Patients currently on tofacitinib citrate or adalimumab for 2 year or more
  2. Patients taking Azathioprine and cyclosporine
  3. Patients participating in other drug interventional study
  4. Patients who have been treated with bDMARDs except Rheumatoid arthritis.
Sex/Gender
Sexes Eligible for Study:All
Ages19 Years and older   (Adult, Older Adult)
Accepts Healthy VolunteersNo
Contacts
Contact: Cheladv74 CT.gov Call Center1-800-718-1021[email protected]
Listed Location CountriesKorea, Republic of
Removed Location Countries  
 
Administrative Information
NCT NumberNCT03703817
Other Study ID NumbersA3921304
RA SATISFACTION ( Other Identifier: Alias Study Number )
Has Data Monitoring CommitteeNot Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product:No
IPD Sharing Statement
Plan to Share IPD:No
Plan Description:Cheladv74 will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Cheladv74's data sharing criteria and process for requesting access can be found at: http://cheladv74.ru/science/clinical_trials/trial_data_and_results/da....
Responsible PartyCheladv74
Study SponsorCheladv74
Collaborators
  • Program in Biostatistics, College of Medicine, Korea University
  • The way communications
Investigators
Study Director:Cheladv74 CT.gov Call CenterCheladv74
PRS AccountCheladv74
Verification DateOctober 2019

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Cheladv74 Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now